
Immergo Labs
OperatingImmergo Labs, Inc.
Healthcare · Santa Cruz, CA · Founded 2022
Redefining telehealth for physical therapy
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Principal holders% as the filing states it, Sep 22, 2022
- Aviv Elor50.0%of company
- Mircea Teodorescu25.0%of company
- Sri Kurniawan25.0%of company
Sold to the crowd
- Reg CF · Sep 202268,798 shares at $2.24$154.1K· 113 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
7 people
Ash Robbins leads artificial intelligence design, manages cloud architecture integration, and ensures development meets technical validation. He has extensive development experience in machine learning and cloud computing from bio-inspired robotics to rehabilitation movement and modeling. He previously has worked on robots with adjustable dynamic properties and developing neural data from complex cloud architectures. His focus is on generalization in algorithmic design, using data driven approaches to quantify uncertainty. Robbins is currently a PhD Candidate at UCSC and upon graduation in 2023 will pursue commercialization of Immergo's core technology full time. Robbins works closely with Elor to lead technical operations.

Aviv Elor is the chief research and experience officer at Immergo Labs, where he leads virtual reality development, user experience research, and product validation. He is an award-winning researcher with expertise in the design and validation of virtual environments for physical rehabilitation. Dr. Elor has previously worked in designing immersive experiences from healthcare to entertainment between mixed academic-industry channels with organizations such as the National Institutes of Health, Meta (Facebook/Oculus) Reality Labs, Google Daydream, Warner Bros Entertainment, and Walt Disney Imagineering. After rupturing his own elbow in a national judo match and undergoing reconstructive surgery, he became a passionate developer for assistive technologies towards more accessible, affordable, and accurate physical therapy tools.

Michael is the Chief Executive Officer of Immergo Labs where he leads the business and biomechanics aspects of the company. Dr. Powell has received Bachelors' degress in physics kinesiology, a Master's degree in exercise science with a focus in biomechanics, and a PhD in computer engineering where is research focused on developing machine learning algorithms to estimate joint mechanics during virtual reality rehabilitation. Michael grew up playing sports, sparking his interest in physical performance and recovery which steered his research for the last several years. Now he hopes to take his experience and develop tools to help others in their recovery process.

Greg Gewickey as a Technology Executive and Strategy Advisor at Gewickey Consulting, he engages with clients to develop robust corporate strategies. Greg has more than 35 years of industry experience in strategic planning, technology innovation, product management, and startup acceleration from organizations such as Amazon Web Services, IBM, Philips Electronics, InterActual, Walt Disney, and Warner Bros.

Mircea Teodorescu is a Professor in the Department of Electrical and Computer Engineering at University of California, Santa Cruz. He is a systems engineer and biomechanical specialist with research focus on the development of emerging technologies to improve quality of life from bioengineering, bioelectronics, and robotics.

Sean Wells, DPT, OCS, ATC, CSCS, NSCA-CPT, CNPT, CERTDN is an expert concierge PT and a member of the APTA, NATA, and NSCA. Dr. Wells owns 4 concierge PT practices, has over 10 years of private PT business experience and has led research trials in applying emerging technology to concierge patients and garnering data with products including Nike Strobe glasses, Alter G, and vibration platforms. Through his concierge PT expertise and the hands-on application of the tech for research, Dr. Wells informs the discovery of new needs, tools, or settings.

Sri Kurniawan is the Chair and Professor of Computational Media at UC Santa Cruz, where she leads research and development of assistive technology to help people with special needs maintain a high quality of life. Kurniawan has more than 20 years of experience in human-centered design, research collaborations with companies such as Microsoft, IBM Accessibility Lab, and others. Additionally, Kurniawan specializes in VR rehabilitation and has been involved with five NSF Basic Research Grant Projects over the past decade in designing and evaluating assistive technologies.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 3 of 4 annual reports (FY2022–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form C-ARMay 1, 20250001665160-25-000923EDGAR
- Form C-ARMar 22, 20240001665160-24-000245EDGAR
- Form C-ARMay 1, 20230001665160-23-001086EDGAR
- Form C-UJan 24, 20230001665160-23-000128EDGAR
- Form C/ADec 15, 20220001665160-22-003078EDGAR
- Form C/ASep 22, 20220001665160-22-002466EDGAR
- Form CSep 22, 20220001665160-22-002462EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.